Moderna Appoints Melissa J. Moore, Ph.D., as Chief Scientific Officer of Moderna’s mRNA Research Platform

Moderna Appoints Melissa J. Moore, Ph.D., as Chief Scientific Officer of Moderna’s mRNA Research Platform

September 13, 2016

-Renowned UMass Medical School Professor and Founding Co-Director of the RNA Therapeutics Institute (RTI) to Lead Moderna’s mRNA Biology Research-

-Dr. Moore to Oversee Moderna’s Efforts to Further Advance Its Leading mRNA Platform to Promote Continued Pipeline Expansion and Deliver a New Class of Medicines for Patients-

Boston Business Journal features Flagship's investment in state companies

Boston Business Journal features Flagship's investment in state companies

May 20, 2016

We’re a lot more than venture capital, but we do invest in and grow our community. Our $116.4 million invested into Massachusetts-based companies in our Flagship community in 2015 ranked us atop the Boston Business Journal’s list.

From their article:

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations and $130M Series B

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations and $130M Series B

August 25, 2016

Denali Therapeutics Inc. (“Denali”) today announced several critical milestones in the company’s growth, including its first Clinical Trial Application (“CTA”) to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 million Series B equity financing. 

TransMedics, Inc.

Heartwarming Story: Developing a Better Way to Preserve Organs

Heartwarming Story: Developing a Better Way to Preserve Organs

August 14, 2016

 Read the story from Newsweek, featuring TransMedics Inc., here: http://www.newsweek.com/developing-better-way-preserve-organs-490058

Flagship Partner Dr. Jeremy Springhorn Panel Discussion Transcript

Flagship Partner Dr. Jeremy Springhorn Panel Discussion Transcript

August 12, 2016

In June 2016, Flagship partner Jeremy Springhorn spoke on a panel session, “Beyond the Cutting Edge: How to Enable Life Science Organizations Today for the Societal Challenges of Tomorrow,” at the BIO International Convention in San Francisco.

An edited transcript of his remarks, alongside other respected industry peers, has been published in the August 2016 issue of Life Science Leader.

Axcella to Present at Wedbush PacGrow Healthcare Conference

Axcella to Present at Wedbush PacGrow Healthcare Conference

August 9, 2016

CAMBRIDGE, Mass. – Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Wedbush PacGrow Healthcare Conference in New York, N.Y. The presentation will take place August 16, 2016, at 3:05 p.m. EDT.

About Axcella Health

Flagship Ventures Names Daniel McIntyre Partner

Flagship Ventures Names Daniel McIntyre Partner

June 29, 2016

Industry Veteran Assumes new position to lead strategic communication

CAMBRIDGE, Mass., June 29, 2016 -- Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies.

Evelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company

Evelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company

July 12, 2016

Company will focus on next generation immunotherapies for cancer, autoimmune and inflammatory diseases

Noubar Afeyan, Ph.D., Appointed Chairman; Executive Leadership Team Expanded

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer

July 13, 2016

Cambridge, Mass., July 13, 2016 (PR Newswire) – Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization.

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

June 29, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, Syros has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Syros at the public offering price, less the underwriting discount and commissions, to cover over-allotments, if any. All of the shares are being offered by Syros Pharmaceuticals.